Study Finds Half Of Patients Undergoing Cerebrovascular Stent Placement Respond Poorly To The Antiplatelet Drug Clopidogrel (Plavix)

A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel. Clopidogrel (Plavix) and aspirin are medications routinely prescribed for 1-3 months following cerebrovascular stent placement to combat the risk of blood clots (stent-thrombosis) and reclosure of the artery (re-stenosis).

More: continued here

Filed under: Neurology / Neuroscience on February 7th, 2008